Background：Glembatumumab CR011 is a fully human IgG2 monoclonal antibody mAb that targets cancer cells expressing transmembrane glycoprotein NMB GPNMB, or osteoactivin. It was designed to linke to monomethyl auristatin E MMAE via a valine-citrulline enzyme-cleavable linker to act as an antibody-drug conjugate ADC termed glembatumumab vedotin also known as CDX-011 and CR011-vcMMAE for the treatment of advanced, refractory, or resistant GPNMB-expressing breast cancer. It was originally developed through a partnership between CuraGen and Amgen, using Xenomouse technology licensed from Abgenix and ADC technology licensed from Seattle Genetics. Glembatumumab vedotin was in development through April 2018 by Celldex Therapeutics, who acquired CuraGen in 2009. Development of the ADC was discontinued in April 2018 after missing the primary endpoint of its study and failed to help women with tough-to-treat metastatic triple-negative breast cancers TNBC stay both alive and progression-free for longer than Roche Holding AG’s Xeloda capecitabine.
Alternative Names：CDX-011 DOX, CR011, glembatumumab vedotin ADC,
